HomeCompareCAH vs PKI

CAH vs PKI: Dividend Comparison 2026

CAH yields 0.99% · PKI yields 0.24%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CAH wins by $1.8K in total portfolio value
10 years
CAH
CAH
● Live price
0.99%
Share price
$206.31
Annual div
$2.04
5Y div CAGR
5.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.6K
Annual income
$185.04
Full CAH calculator →
PKI
PKI
● Live price
0.24%
Share price
$115.24
Annual div
$0.28
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$0.02
Full PKI calculator →

Portfolio growth — CAH vs PKI

📍 CAH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAHPKI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAH + PKI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CAH pays
PKI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAH
Annual income on $10K today (after 15% tax)
$83.95/yr
After 10yr DRIP, annual income (after tax)
$157.28/yr
PKI
Annual income on $10K today (after 15% tax)
$20.65/yr
After 10yr DRIP, annual income (after tax)
$0.02/yr
At 15% tax rate, CAH beats the other by $157.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAH + PKI for your $10,000?

CAH: 50%PKI: 50%
100% PKI50/50100% CAH
Portfolio after 10yr
$20.6K
Annual income
$92.53/yr
Blended yield
0.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CAH right now

CAH
Analyst Ratings
18
Buy
15
Hold
Consensus: Buy
Price Target
$252.33
+22.3% upside vs current
Range: $220.00 — $275.00
Altman Z
4.8
Piotroski
5/9
PKI
Analyst Ratings
13
Buy
18
Hold
Consensus: Hold
Price Target
$166.57
+44.5% upside vs current
Range: $145.00 — $202.00
Altman Z
2.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAH buys
0
PKI buys
0
No recent congressional trades found for CAH or PKI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAHPKI
Forward yield0.99%0.24%
Annual dividend / share$2.04$0.28
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR5.6%-50%
Portfolio after 10y$21.6K$19.7K
Annual income after 10y$185.04$0.02
Total dividends collected$1.4K$24.00
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyHold
Analyst price target$252.33$166.57

Year-by-year: CAH vs PKI ($10,000, DRIP)

YearCAH PortfolioCAH Income/yrPKI PortfolioPKI Income/yrGap
1← crossover$10,804$104.30$10,712$12.15+$92.00CAH
2$11,672$111.21$11,468$6.08+$204.00CAH
3$12,607$118.57$12,274$3.04+$333.00CAH
4$13,616$126.40$13,135$1.52+$481.00CAH
5$14,704$134.73$14,055$0.76+$649.00CAH
6$15,877$143.59$15,039$0.38+$838.00CAH
7$17,142$153.02$16,092$0.19+$1.1KCAH
8$18,504$163.04$17,218$0.10+$1.3KCAH
9$19,973$173.70$18,424$0.05+$1.5KCAH
10$21,557$185.04$19,713$0.02+$1.8KCAH

CAH vs PKI: Complete Analysis 2026

CAHHealthcare

Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

Full CAH Calculator →

PKIStock

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Full PKI Calculator →
📬

Get this CAH vs PKI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAH vs SCHDCAH vs JEPICAH vs OCAH vs KOCAH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.